Edgewise Therapeutics Inc (EWTX)
20.24
-0.65
(-3.11%)
USD |
NASDAQ |
May 09, 13:31
Edgewise Therapeutics Enterprise Value: 1.627B for May 8, 2024
Enterprise Value Chart
Historical Enterprise Value Data
Date | Value |
---|---|
May 08, 2024 | 1.627B |
May 07, 2024 | 1.658B |
May 06, 2024 | 1.575B |
May 03, 2024 | 1.499B |
May 02, 2024 | 1.478B |
May 01, 2024 | 1.452B |
April 30, 2024 | 1.352B |
April 29, 2024 | 1.269B |
April 26, 2024 | 1.187B |
April 25, 2024 | 1.166B |
April 24, 2024 | 1.182B |
April 23, 2024 | 1.139B |
April 22, 2024 | 1.086B |
April 19, 2024 | 1.100B |
April 18, 2024 | 1.120B |
April 17, 2024 | 1.139B |
April 16, 2024 | 1.230B |
April 15, 2024 | 1.216B |
April 12, 2024 | 1.206B |
April 11, 2024 | 1.217B |
April 10, 2024 | 1.165B |
April 09, 2024 | 1.189B |
April 08, 2024 | 1.253B |
April 05, 2024 | 1.261B |
April 04, 2024 | 1.220B |
Date | Value |
---|---|
April 03, 2024 | 1.404B |
April 02, 2024 | 1.327B |
April 01, 2024 | 1.359B |
March 28, 2024 | 1.380B |
March 27, 2024 | 1.354B |
March 26, 2024 | 1.278B |
March 25, 2024 | 1.171B |
March 22, 2024 | 1.195B |
March 21, 2024 | 1.254B |
March 20, 2024 | 1.243B |
March 19, 2024 | 1.189B |
March 18, 2024 | 1.128B |
March 15, 2024 | 1.257B |
March 14, 2024 | 1.271B |
March 13, 2024 | 1.303B |
March 12, 2024 | 1.332B |
March 11, 2024 | 1.241B |
March 08, 2024 | 1.279B |
March 07, 2024 | 1.333B |
March 06, 2024 | 1.264B |
March 05, 2024 | 1.262B |
March 04, 2024 | 1.264B |
March 01, 2024 | 1.236B |
February 29, 2024 | 1.202B |
February 28, 2024 | 1.232B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
15.26M
Minimum
May 25 2022
1.658B
Maximum
May 07 2024
453.83M
Average
289.44M
Median
Aug 23 2022
Enterprise Value Benchmarks
Sarepta Therapeutics Inc | 12.38B |
PTC Therapeutics Inc | 1.788B |
Fate Therapeutics Inc | 52.01M |
Viking Therapeutics Inc | 7.849B |
Regenxbio Inc | 541.45M |
Enterprise Value Related Metrics
Net Income (Quarterly) | -30.14M |
Total Expenses (Quarterly) | 33.86M |
EPS Diluted (Quarterly) | -0.47 |
Earnings Yield | -7.81% |